english.prescrire.org > Spotlight > 100 most recent > Tripoliponumab: French firm Neuronodev demands withdrawal of marketing authorisation and approves 150 million euros for patients

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90